Dr. Nagourney's Blog


Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Cancer Patients, Genetic Testing and Clinical Outcomes
By Robert A. Nagourney, MD
Two years ago in this blog, I described a young man with an aggressive non-small cell lung cancer. Following his diagnosis he was screened for EGFR mutation (the target of Erlotinib [Tarceva]) and ALK gene rearrangement (the target of...
ASCO Update: Personalized Cancer Therapy – Our Contributions
By Robert A. Nagourney, MD
As part of our ongoing blog postings we like to include recent presentations and publications. On July 9, I described our ASCO...
Functional Profiling Identifies Accurate Genomic Findings
By Robert A. Nagourney, MD
The 2013 American Society of Clinical Oncology annual meeting, held May 31 – June 1, in Chicago, afforded the opportunity to...
Gee (G719X) Whiz: Novel Mutations and Response to Targeted Therapies
By Robert A. Nagourney, MD
In a recent online forum a patient described her experience using Tarceva as a therapy for an EGFR mutation negative lung...
The False Economy of Genomic Analyses
By Robert A. Nagourney, MD
We are witness to a revolution in cancer therapeutics. Targeted therapies, named for their capacity to target specific tumor...
Novel Lung Cancer Treatments — Crizotinib for Some NSCLC Patients
By Robert A. Nagourney, MD
Recent reports have described the striking activity of a novel Pfizer compound known as Crizotinib. The compound is an...
Targeted Therapies — The Next Chapter
By Robert A. Nagourney, MD
Within this blog, we have intermittently reviewed the concept of targeted therapies. To reiterate, these are classes of drugs...

browse by topic

Select A topic

View All Topics

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.